Adagene Inc. (ADAG) Opens Phase 1 Trial of ADG126 Combination in Colorectal Cancer

Adagene Inc. (ADAG) and City of Hope began a Phase 1 trial of ivonescimab and ADG126 for advanced colorectal cancer. The study will include up to 36 patients.

Original reporting
Published Nov 17, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 1:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Adagene Inc. (ADAG) Opens Phase 1 Trial of ADG126 Combination in Colorectal Cancer — source image
Decision brief

The 30-second read

$ADAGNeutralLow
01

Why it matters

This is a pipeline milestone that can support longer-term valuation optionality, but it is not yet evidence of clinical benefit.

02

Market read

Traders may view the trial start as incremental pipeline progress, but without interim data it is unlikely to drive a major repricing immediately.

03

What to watch

Key missing items are dosing schedule, safety endpoints, and whether ivonescimab plus ADG126 has prior signals in this exact setting.

Relevance 5/10Novelty 5/10Timing: today, pipeline update with trial initiation details

Background

The piece describes the launch of an investigator-initiated Phase 1 trial for ivonescimab plus ADG126 in advanced microsatellite stable colorectal cancer.

Company-level read

Ticker impact

$ADAGNeutralMedium confidence
Context

Adagene launched an investigator-initiated Phase 1 trial combining ivonescimab and ADG126 in advanced microsatellite stable colorectal cancer, enrolling up to 36 patients.

Expected impact

Likely limited near-term reaction as investors wait for dose selection, safety, and any antitumor signals.

Evidence & confidence

The article discloses a Phase 1 start and enrollment size only. Without interim results, the news mainly updates pipeline progress rather than fundamentals.

Market effects

Adds incremental momentum to the oncology immunotherapy and colorectal cancer trial landscape, but with no cross-company read-through provided.

No specific regional market linkage mentioned.

Limited global impact; this is a single-company early clinical development update.

Counterpoint

Phase 1 investigator-initiated studies can be slower and less predictive than company-sponsored pivotal programs, so the market may discount the catalyst.

Key entities

  • Adagene Inc.

    Sponsor of the Phase 1 trial for ivonescimab and ADG126 in advanced microsatellite stable colorectal cancer.

  • City of Hope

    Co-launched the investigator-initiated Phase 1 trial with Adagene.

  • ADG126

    Adagene’s investigational candidate used in combination in the Phase 1 study.

  • ivonescimab

    Combination partner in the Phase 1 trial.

Related articles

$ADAGLowAI 8/10

Adagene completes enrollment in phase 2 trial of muzastotug

Adagene Inc. (ADAG) completed enrollment in a Phase 2 trial of muzastotug, an anti-CTLA-4 antibody therapy, combined with Merck’s KEYTRUDA for late-line colorectal cancer. The trial enrolled 60 patients, with results expected in early 2027. The FDA confirmed Phase 3 trial design elements, and Sanofi invested in the trial. Muzastotug has FDA Fast Track designation.